Back to dashboard
CommercialPrior AuthMedium impact

Additional drugs to have site-of-care requirement for most commercial members, starting June 1

BCBS Michigan·MI · Rheumatology, Gastroenterology, Neurology +2 more·Prior Authorization
Effective date
Jun 1, 2026
We identified it
Jun 16, 2026
Days to comply

Summary

Starting June 1, 2026, Blue Cross Blue Shield of Michigan and Blue Care Network are adding site-of-care requirements for 12 specialty drugs already requiring prior authorization. Providers must now specify and justify the administration site when requesting prior authorization, with automatic approval for office, ambulatory infusion center, or home settings, but additional documentation required for hospital outpatient settings.

Action Required

Action needed
By June 1, 2026: Clinical and billing teams must update prior authorization workflows to include site-of-care selection when requesting approval for the listed specialty drugs (eculizumab, ustekinumab variants, and cipaglucosidase alfa). Ensure staff are trained to select appropriate administration sites (office, ambulatory center, or home) for automatic approval, or prepare additional documentation if hospital outpatient setting is required. Update internal processes to verify group participation in Medical Drug Prior Authorization Program using the Specialty Pharmacy Master Opt-in/out Group list.

Affected Billing Codes

Q5151
Q9999
J1203
Q9997
Q9998
Q5099
Q5138